From the biological point of view, anti-BRAF targeted therapies have been recognized to positively modulate the immune regulation, by promoting T-cell infiltration with reduction of regulatory T-cells, inducing melanoma antigen-expression, and restoring the impaired MHC-I surface expression, thus reducing the immunosuppression and immune escape associated with the BRAF mutated oncogenic pathway [52]. The gene discussed is BRAF; the disease is melanoma.